The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | SIMPLIFY studies: analysis of the meaningful symptomatic change in patients with myelofibrosis
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, comments on the meaningful symptomatic change analyzed in patients with myelofibrosis from the SIMPLIFY studies (NCT01969838 and NCT02101268). Dr Mesa highlights the importance of looking at both individual symptoms and total symptom scores to get a more holistic view of how individual patients with myelofibrosis improve or deteriorate. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
